Lexeo Therapeutics (NASDAQ:LXEO) Posts Earnings Results, Misses Estimates By $0.01 EPS

Lexeo Therapeutics (NASDAQ:LXEO) posted its quarterly earnings data on Wednesday. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.01), FiscalAI reports.

Lexeo Therapeutics Stock Down 0.2%

Shares of NASDAQ:LXEO traded down $0.01 during midday trading on Thursday, hitting $4.86. 302,889 shares of the stock traded hands, compared to its average volume of 951,131. The business’s 50 day moving average is $4.64 and its two-hundred day moving average is $5.65. The stock has a market capitalization of $381.61 million, a PE ratio of -3.34 and a beta of 1.46. Lexeo Therapeutics has a one year low of $3.99 and a one year high of $10.99.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on LXEO shares. Weiss Ratings lowered Lexeo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 30th. Chardan Capital raised Lexeo Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 28th. Wall Street Zen raised shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, JPMorgan Chase & Co. cut their price target on shares of Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating for the company in a research report on Thursday, June 25th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Lexeo Therapeutics currently has an average rating of “Buy” and an average price target of $18.75.

Insider Buying and Selling

In other news, CEO Richard Nolan Townsend sold 25,947 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $4.48, for a total transaction of $116,242.56. Following the transaction, the chief executive officer directly owned 377,817 shares of the company’s stock, valued at approximately $1,692,620.16. The trade was a 6.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Narinder Pal Bhalla sold 22,306 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $4.42, for a total value of $98,592.52. Following the completion of the sale, the insider directly owned 82,194 shares of the company’s stock, valued at $363,297.48. The trade was a 21.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 62,204 shares of company stock worth $280,089. Corporate insiders own 2.00% of the company’s stock.

Institutional Investors Weigh In On Lexeo Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LXEO. The Manufacturers Life Insurance Company purchased a new stake in shares of Lexeo Therapeutics during the fourth quarter valued at $190,000. Police & Firemen s Retirement System of New Jersey increased its stake in shares of Lexeo Therapeutics by 171.1% in the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 16,373 shares of the company’s stock worth $163,000 after purchasing an additional 10,333 shares in the last quarter. Intech Investment Management LLC boosted its stake in shares of Lexeo Therapeutics by 19.5% in the fourth quarter. Intech Investment Management LLC now owns 14,188 shares of the company’s stock worth $141,000 after acquiring an additional 2,317 shares during the period. Brevan Howard Capital Management LP purchased a new position in Lexeo Therapeutics in the 3rd quarter worth approximately $122,000. Finally, Bank of America Corp DE grew its holdings in Lexeo Therapeutics by 6.1% during the 3rd quarter. Bank of America Corp DE now owns 28,279 shares of the company’s stock valued at $188,000 after buying an additional 1,626 shares in the last quarter. 60.67% of the stock is owned by hedge funds and other institutional investors.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.